Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
Key Highlights
- ➤GSK selected hepatology candidate, triggering Wave Life Sciences (WVE) milestone payment
- ➤Wave Life Sciences (WVE) will receive a $12 million milestone payment
- ➤Wave Life Sciences (WVE) eligible for up to $330 - $375 million per program
- ➤Three additional GSK collaboration programs advancing toward candidate selection
Expert Statements
Paul Bolno, MD, MBA
“The advancement of this development candidate by GSK reflects the recognition of Wave’s differentiated technology, including our best-in-class SpiNA design siRNA.”
Paul Bolno, MD, MBA
“Our SpiNA siRNA compounds demonstrate superior pharmacology, including improved potency, durability and Ago2 loading versus comparator formats.”
Paul Bolno, MD, MBA
“Our collaboration with GSK continues to leverage the versatility of our PRISM™ platform coupled with human genetic insights to advance novel oligonucleotide therapeutics.”
Paul Bolno, MD, MBA
“With this new hepatic program now transitioning to candidate, our collaboration momentum continues as we have three additional programs rapidly advancing towards candidate selection, all leveraging our proprietary PRISM chemistry.”
Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing
CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that as part of the companies’ research collaboration, GSK has selected a candidate for a hepatology indication to transition into GSK’s development pipeline. This program was developed using Wave’s proprietary SpiNA design GalNAc-siRNA.
Get started
Create a free account to read the full story.